secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lyra Therapeutics, Inc. (LYRA)
CIK:        0001327273
Form:       8-K
Filed at:   2022-10-26T23:59:59+00:00
Accession:  0000950170-22-020211
Event type: other_material
Sentiment:  negative
Materiality: 0.80
Item codes: 4.02
LLM model:  deepseek-v4-flash:cloud@v2

Lyra Therapeutics restates Q1/Q2 2022 financials due to $5M milestone error
---------------------------------------------------------------------------

- Audit Committee concludes Q1 and Q2 2022 financials no longer reliable due to $5.0M milestone revenue recognition error from LianBio agreement.
- Restatement will correct the treatment of variable consideration; cash position unchanged.
- Material weakness identified in internal controls over accounting for complex, nonrecurring transactions.
- Company expects to file restated financials as soon as practicable.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1327273/000095017022020211/0000950170-22-020211-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1327273/000095017022020211/lyra-20221026.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-020211

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer